Business Wire

Mastercard and OCTO Join Forces to Promote Responsible Driving Through Loyalty Programs

Share

Mastercard and OCTO, a global leader in advanced telematics solutions and data analytics services for the insurance and automotive sectors, today announce a collaboration aimed at redefining the interaction between insurance companies and customers by encouraging safer driving behaviors through an innovative loyalty program.

The partnership involves the integration of Mastercard’s SessionM – a platform designed to support businesses in managing customer loyalty and engagement – with OCTO’s patented scoring models, which assess driving behavior using either physical devices (black boxes) or digital solutions (apps).

This agreement has a dual objective: for drivers, it provides tangible benefits such as discounts on auto, home, and travel insurance, as well as other rewards, in exchange for safe and responsible driving. For insurance companies, it enhances customer engagement and loyalty, reduces portfolio risk, and helps control costs through a continuous and interactive relationship with the insured.

The promotion of responsible driving behavior not only has a direct impact on road safety but also represents a significant contribution to environmental and social sustainability goals.

Luca Corti, Country Manager Italy, Mastercard, commented: "We are excited to collaborate with OCTO putting technology at the service of safer and more conscious mobility. Through our innovative solutions, we enable data-driven loyalty models that reward positive behavior and strengthen the relationship between businesses and customers. This partnership confirms Mastercard’s commitment to driving the evolution of key sectors of the economy, helping to create increasingly connected and value ecosystems."

Corrado Sciolla, CEO of OCTO Group, adds: “The partnership with Mastercard strengthens our commitment to smarter and more sustainable mobility. Together, we are offering insurance companies a new, more proactive and engaging way to interact with their customers, by providing an effective tool to reward positive behavior, helping drivers improve road safety and reduce accidents and emissions. In a context where companies are increasingly focused on social and environmental goals, OCTO confirms its role as a strategic partner for responsible innovation in the entire insurance sector and in telematics applied to mobility.”

Thanks to its collaboration with Mastercard – a global leader in the loyalty sector, with over 1,400 client companies and a network of more than 900 specialists – SessionM will provide OCTO and its clients with a scalable and highly reliable SaaS platform capable of managing complex data and loyalty programs on a global scale. With over 350 billion loyalty points managed, 3 billion API calls annually, and 1.3 billion marketing impressions generated each year, Mastercard further strengthens its position in the insurance sector alongside innovative partners like OCTO.

– END –

Mastercard
Mastercard powers economies and empowers people in over 200 countries and territories worldwide. Together with our customers, we are building a sustainable economy where everyone can thrive. We support a wide range of digital payment solutions, making transactions secure, simple, smart, and accessible. Our technology and innovation, partnerships, and networks combine to offer a unique suite of products and services that help individuals, businesses, and governments reach their fullest potential.
www.mastercard.com

OCTO
For over 20 years, we have been developing integrated solutions that enable us to support our clients in seizing the opportunities offered by smart mobility and digital transformation. Thanks to an innovative approach based on Artificial Intelligence, we have developed advanced algorithms for accident detection, driving behavior analysis, claims management, and consumption optimization. These solutions allow us to meet the needs of key markets, such as insurance and mobility, with a strong focus on modularity and customization. Our scalable and modular data analytics platform delivers solutions for the Insurtech and mobility markets, helping partner companies transform the way they manage and grow their business. Today, OCTO serves over 6 million connected users and owns the world’s largest telematics database, with 610 billion kilometers of driving data and over 525,000 certified claims.
octotelematics.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250521772894/en/

Contacts

Mastercard
Giuliana Abbate
E. Giuliana.Abbate@mastercard.com

Omnicom PR Group
Mastercard Press Office
T. +39 02 6241 1911
E. mln.mastercard@fleishmaneurope.com

OCTO Media Contact
Adriana Zambon
press@octotelematics.com
Phone +39 339.3995640

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release

Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t

Qualcomm Announces Quarterly Cash Dividend17.10.2025 16:00:00 EEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye